NCT07623824尚未招募3 期
A Randomized, Parallel, Open-label, Multicenter, Positive-controlled, Superiority Phase III Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.0 个研究点目标入组 154 人开始时间: 2026年5月31日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 154
研究概览
简要总结
he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.
详细描述
This study is a randomized, parallel, open-label, multicenter, positive-controlled, superiority-designed Phase III clinical study evaluating the efficacy and safety of octreotide long-acting injection in patients with acromegaly. The purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in treating acromegaly. Patients will be randomized to SYHX2008 cohort or Octreotide Microspheres(Sandostatin LAR®) cohort. A total of 154 participants are expected to be enrolled. The study will consist of a maximum 4-week screening/Baseline period, followed by 28-week treatment period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female participants aged 18 to 80 years (including boundary values)
- •Diagnosed with acromegaly, currently in the active stage of the disease (for patients who have not undergone pituitary tumor surgery before, MRI shows a pituitary mass, fasting GH ≥ 2.5 ng/mL and IGF-1 index ≥ 1.3; for patients who have undergone pituitary tumor surgery, fasting GH ≥ 2.5 ng/mL and IGF-1 index ≥ 1.3)；
排除标准
- •Have received pituitary radiotherapy within the 5 years prior to screening
- •Have undergone major surgery (including pituitary surgery) within 6 months prior to screening or are expected to require surgery (including pituitary surgery) or radiotherapy during the study period
- •Within three months before the screening, participants received drugs such as long-acting lanretide, long-acting octreotide, pervesomone, and cabergoline, or traditional Chinese medicines for treating acromegaly. Receive bromocriptine within one month before screening; Received short-acting octreotide or lanretide short-acting preparations for treatment within 7 days before screening; Or have received any other investigational drug within 30 days before screening or within 5 half-lives (whichever is longer)
- •Previous failure to respond to octreotide or lantreotide monotherapy (defined as: after at least 3 months of treatment with octreotide microspheres ≥30 mg or lantreotide ≥120 mg, or after at least 3 months of treatment with parietide microspheres ≥40 mg, random GH ≥2.5 ng/mL and/or IGF-1 index ≥1.3) or history of intolerance.
- •Participants with obvious visual field defects caused by optic chiasm compression and requiring surgical intervention
- •HbA1c>8.5%
研究者
相似试验
尚未招募
1 期
A Single Ascending Dose Study of SYH2082 Injection in Healthy ParticipantsOverweight or ObesityNCT07532655CSPC ZhongQi Pharmaceutical Technology Co., Ltd.44
招募中
3 期
A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed HyperlipidemiaNCT07421297CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.760
已完成
2 期
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed HyperlipidemiaNCT07421232CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.156
尚未招募
3 期
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering TherapyNCT07421284CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.900
进行中（未招募）
1 期
A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid TumorsLiver CancerNCT07362264Nanjing Sanhome Pharmaceutical, Co., Ltd.50